Antigall 300 is indicated for:
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Antigall 300 contains Ursodeoxycholic Acid (UDCA), a naturally occurring hydrophilic bile acid derived from cholesterol. It normally constitutes only a small proportion of the bile acids found in human bile. Antigall 300 increases the proportion of Ursodeoxycholic Acid in a dose-dependent manner, allowing it to become the predominant bile acid and helping to replace or displace potentially toxic hydrophobic bile acids that may accumulate in cholestatic liver diseases.
In addition to reducing the concentration of toxic bile acids, Ursodeoxycholic Acid provides cytoprotective effects on injured bile duct epithelial cells (cholangiocytes), helps inhibit hepatocyte apoptosis, modulates immune responses, and stimulates bile secretion by hepatocytes and cholangiocytes.
Antigall 300 also lowers the ratio of cholesterol to bile salts and phospholipids in bile, thereby reducing cholesterol saturation and promoting the dissolution of cholesterol-rich gallstones.
During the first 3 months of treatment, liver function tests including AST (SGOT), ALT (SGPT), and γ-GT should be monitored by a physician every 4 weeks. Afterward, monitoring should generally be performed every 3 months.
Ursodeoxycholic Acid should not be used when the gallbladder cannot be adequately visualized on X-ray, or in patients with calcified gallstones, impaired gallbladder contractility, or frequent episodes of biliary colic.
If diarrhea develops, the dose should be reduced. Persistent diarrhea may require discontinuation of treatment.
Patients with rare hereditary conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
The recommended adult dose is 13–15 mg/kg/day, administered in 2–4 divided doses with food.
Adults and elderly: The usual dose is 6–12 mg/kg/day, given either as a single dose at bedtime or in divided doses. In obese patients, the dose may be increased to 15 mg/kg/day when clinically appropriate.
Treatment may be required for up to 2 years, depending on the size of the gallstones. Therapy should generally be continued for 3 months after apparent dissolution of the stones.
For patients undergoing rapid weight loss, the recommended dose is 600 mg daily, given as 300 mg twice daily.
No specific adjustment of the adult dosage is generally indicated. However, appropriate precautions should be considered based on the patient's clinical condition.
The recommended dose is 20 mg/kg/day, divided into 2–3 doses. If necessary, the dose may be increased to 30 mg/kg/day.
There are no specific dosage recommendations for patients with hepatic or renal impairment. Ursodeoxycholic Acid therapy has not generally been associated with liver damage; however, patients should be monitored appropriately.
Rare adverse effects may include:
Adequate clinical data regarding the use of Ursodeoxycholic Acid during pregnancy, particularly during the first trimester, are limited. Animal studies have indicated potential teratogenic effects during early pregnancy. Therefore, Ursodeoxycholic Acid should only be used during pregnancy when clearly necessary. Treatment should be stopped if pregnancy occurs unless continued treatment is specifically advised by a physician.
It is not established whether Ursodeoxycholic Acid passes into human breast milk. Therefore, it should generally not be used during breastfeeding unless medically necessary. If treatment is considered essential, discontinuation of breastfeeding may be required.
These medicines may reduce the absorption and effectiveness of Ursodeoxycholic Acid.
Ursodeoxycholic Acid may increase the intestinal absorption of ciclosporin. In some cases, it may decrease the absorption of ciprofloxacin.
It may also reduce the peak plasma concentration (Cmax) and overall exposure (AUC) of the calcium-channel blocker nitrendipine. A reduction in the therapeutic effect of dapsone has also been reported.
Oral contraceptives, estrogenic hormones, and cholesterol-lowering medicines such as clofibrate may increase the risk of biliary stone formation, which may counteract the intended effect of Ursodeoxycholic Acid when used for gallstone dissolution.
Diarrhea may occur following an overdose. Other symptoms are generally unlikely because absorption of Ursodeoxycholic Acid decreases as the dose increases, resulting in greater elimination through the feces.
Specific treatment is usually not required. If diarrhea occurs, treatment should focus on maintaining adequate fluid and electrolyte balance. Ion-exchange resins may be considered to bind bile acids in the intestine. Monitoring of liver function may also be recommended.
Store in a cool, dry place and protect from light. Keep the medicine out of the reach of children
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.